Income statement
EUR
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 258M | 262M | 275M | 287M | 250M |
| Gross Profit | 76M | 65M | 79M | 88M | 69M |
| Operating Income | 28M | 25M | 40M | 48M | 32M |
| EBITDA | 47M | 40M | 55M | 65M | 53M |
| Net Income | 16M | 13M | 29M | 40M | 25M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.51
+0.00% today
1Y Change
-17.76%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stratec SE (STSEY) is a Healthcare stock with a market cap of $210.00M and listed on OTC. The stock last traded around $5.51 and down 17.8% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of -75.7%, a dividend yield of 3.4%. What stands out right now is revenue -1.6%, EPS -75.7%, free cash flow +1425.4% with operating margin 3.9% and ROIC -0.1%. The dividend matters to the case here, with a current yield around 3.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STSEY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STSEY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STSEY Max Drawdown
-25.37%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STSEY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$250.1M
-13.0% YoY
FY Net Income
$25.2M
-37.0% YoY
Free Cash Flow
$6.3M
-85.5% YoY
Revenue Growth
-1.6%
EPS Growth
-75.7%
Gross Margin
25.6%
Net Margin
-0.1%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 258M | 262M | 275M | 287M | 250M |
| Gross Profit | 76M | 65M | 79M | 88M | 69M |
| Operating Income | 28M | 25M | 40M | 48M | 32M |
| EBITDA | 47M | 40M | 55M | 65M | 53M |
| Net Income | 16M | 13M | 29M | 40M | 25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47M | 34M | 23M | 47M | 38M |
| Total Assets | 445M | 467M | 398M | 369M | 332M |
| Total Liabilities | 203M | 233M | 172M | 163M | 159M |
| Shareholder Equity | 243M | 233M | 225M | 206M | 173M |
| Total Debt | 131M | 141M | 87M | 85M | 110M |
| Net Debt | 83M | 108M | 64M | 38M | 72M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
-49.8% YoY
Capital Expenditures
26M
-26.4% YoY
Free Cash Flow
6M
-85.5% YoY
Key ratios
Gross Margin
25.6%
Operating Margin
3.9%
Net Margin
-0.1%
ROE
-0.1%
Debt / Equity
0.56x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.